Annual Revenue
$743.00 K
-$67.00 K-8.27%
December 31, 2023
Summary
- As of February 7, 2025, CANF annual revenue is $743.00 thousand, with the most recent change of -$67.00 thousand (-8.27%) on December 31, 2023.
- During the last 3 years, CANF annual revenue has fallen by -$20.00 thousand (-2.62%).
- CANF annual revenue is now -80.55% below its all-time high of $3.82 million, reached on December 31, 2018.
Performance
CANF Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
N/A
June 30, 2024
Summary
- CANF quarterly revenue is not available.
Performance
CANF Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Related metrics
TTM Revenue
N/A
June 30, 2024
Summary
- CANF TTM revenue is not available.
Performance
CANF TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
CANF Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.3% | - | - |
| 3 y3 years | -2.6% | - | - |
| 5 y5 years | -80.5% | - | - |
CANF Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.9% | at low | ||||
| 5 y | 5-year | -63.4% | at low | ||||
| alltime | all time | -80.5% | +351.1% |
Can-Fite BioPharma Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $743.00 K(-8.3%) | $155.00 K(-20.9%) | $743.00 K(-5.4%) |
| Sep 2023 | - | $196.00 K(0.0%) | $785.00 K(-1.0%) |
| Jun 2023 | - | $196.00 K(0.0%) | $793.00 K(-1.0%) |
| Mar 2023 | - | $196.00 K(-0.5%) | $801.00 K(-1.1%) |
| Dec 2022 | $810.00 K(-5.0%) | $197.00 K(-3.4%) | $810.00 K(-0.9%) |
| Sep 2022 | - | $204.00 K(0.0%) | $817.00 K(-5.4%) |
| Jun 2022 | - | $204.00 K(-0.5%) | $864.00 K(-5.1%) |
| Mar 2022 | - | $205.00 K(+0.5%) | $910.00 K(+6.7%) |
| Dec 2021 | $853.00 K(+11.8%) | $204.00 K(-18.7%) | $853.00 K(+6.8%) |
| Sep 2021 | - | $251.00 K(+0.4%) | $799.00 K(+5.3%) |
| Jun 2021 | - | $250.00 K(+68.9%) | $759.00 K(+6.5%) |
| Mar 2021 | - | $148.00 K(-1.3%) | $713.00 K(-6.6%) |
| Dec 2020 | $763.00 K(-62.5%) | $150.00 K(-28.9%) | $763.00 K(-5.2%) |
| Sep 2020 | - | $211.00 K(+3.4%) | $805.00 K(-53.9%) |
| Jun 2020 | - | $204.00 K(+3.0%) | $1.75 M(-9.6%) |
| Mar 2020 | - | $198.00 K(+3.1%) | $1.93 M(-5.0%) |
| Dec 2019 | $2.03 M(-46.8%) | - | - |
| Dec 2019 | - | $192.00 K(-83.3%) | $2.03 M(-4.6%) |
| Sep 2019 | - | $1.15 M(+196.1%) | $2.13 M(-41.0%) |
| Jun 2019 | - | $389.00 K(+30.1%) | $3.61 M(+3.4%) |
| Mar 2019 | - | $299.00 K(+3.5%) | $3.49 M(-8.7%) |
| Dec 2018 | $3.82 M | - | - |
| Dec 2018 | - | $289.00 K(-89.0%) | $3.82 M(+5.6%) |
| Sep 2018 | - | $2.63 M(+873.7%) | $3.62 M(+132.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $270.00 K(-57.3%) | $1.55 M(+14.9%) |
| Mar 2018 | - | $632.00 K(+643.5%) | $1.35 M(+71.5%) |
| Dec 2017 | $789.00 K(+378.2%) | - | - |
| Dec 2017 | - | $85.00 K(-85.0%) | $789.00 K(+13.1%) |
| Sep 2017 | - | $568.00 K(+735.3%) | $697.70 K(+267.2%) |
| Jun 2017 | - | $68.00 K(0.0%) | $190.00 K(+7.7%) |
| Mar 2017 | - | $68.00 K(-1179.4%) | $176.40 K(+6.9%) |
| Dec 2016 | $165.00 K(+0.2%) | - | - |
| Dec 2016 | - | -$6300.00(-110.4%) | $165.00 K(-16.8%) |
| Sep 2016 | - | $60.30 K(+10.8%) | $198.30 K(-2.8%) |
| Jun 2016 | - | $54.40 K(-3.9%) | $204.00 K(-7.8%) |
| Mar 2016 | - | $56.60 K(+109.6%) | $221.30 K(+34.4%) |
| Dec 2015 | $164.70 K(-64.9%) | - | - |
| Dec 2015 | - | $27.00 K(-59.1%) | $164.70 K(+19.6%) |
| Sep 2015 | - | $66.00 K(-7.9%) | $137.70 K(+92.1%) |
| Jun 2015 | - | $71.70 K(-35.6%) | $71.70 K(-85.3%) |
| Dec 2011 | $469.00 K(-37.1%) | - | - |
| Dec 2011 | - | $111.40 K(-6.5%) | $488.50 K(-7.7%) |
| Sep 2011 | - | $119.10 K(-8.8%) | $529.10 K(-1.9%) |
| Jun 2011 | - | $130.60 K(+2.5%) | $539.50 K(+31.9%) |
| Mar 2011 | - | $127.40 K(-16.2%) | $408.90 K(+45.3%) |
| Dec 2010 | $745.20 K | - | - |
| Dec 2010 | - | $152.00 K(+17.4%) | $281.50 K(+117.4%) |
| Sep 2010 | - | $129.50 K | $129.50 K |
FAQ
- What is Can-Fite BioPharma annual revenue?
- What is the all time high annual revenue for Can-Fite BioPharma?
- What is Can-Fite BioPharma annual revenue year-on-year change?
- What is the all time high quarterly revenue for Can-Fite BioPharma?
- What is the all time high TTM revenue for Can-Fite BioPharma?
What is Can-Fite BioPharma annual revenue?
The current annual revenue of CANF is $743.00 K
What is the all time high annual revenue for Can-Fite BioPharma?
Can-Fite BioPharma all-time high annual revenue is $3.82 M
What is Can-Fite BioPharma annual revenue year-on-year change?
Over the past year, CANF annual revenue has changed by -$67.00 K (-8.27%)
What is the all time high quarterly revenue for Can-Fite BioPharma?
Can-Fite BioPharma all-time high quarterly revenue is $2.63 M
What is the all time high TTM revenue for Can-Fite BioPharma?
Can-Fite BioPharma all-time high TTM revenue is $3.82 M